Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francis Giles

Showing results (21-30 of 174) with videos related to

Pageof 18
Sort By:
Drug Design, Development and Therapy|November 19, 2009
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinibRonan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, et al.
Cancer|January 28, 2004
Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignanciesApostolia-Maria Tsimberidou, Francis Giles, Jorge Romaguera, et al.
Cancer|January 13, 2004
Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center seriesApostolia-Maria Tsimberidou, Francis Giles, Madeleine Duvic, et al.
Annals of Internal Medicine|December 21, 2006
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistanceHagop M Kantarjian, Moshe Talpaz, Francis Giles, et al.
Expert Opinion on Investigational Drugs|November 18, 2008
Deforolimus (AP23573) a novel mTOR inhibitor in clinical developmentMonica Mita, Kamalesh Sankhala, Issam Abdel-Karim, et al.
Leukemia & Lymphoma|April 11, 2015
Novel therapies for myelofibrosisBrady L Stein, Francisco Cervantes, Francis Giles, et al.
Targeted Oncology|April 22, 2009
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agentsKamalesh Sankhala, Alain Mita, Kevin Kelly, et al.
Pediatric Physical Therapy : the Official Publication of the Section on Pediatrics of the American Physical Therapy Association|November 18, 2011
Predictors of Standardized Walking Obstacle Course outcome measures in children with and without developmental disabilitiesKaren M Kott, Sharon L Held, Elizabeth Francis Giles, et al.
Cancer|February 6, 2009
Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulationsTai-Sung Lee, Wanlong Ma, Xi Zhang, et al.
Clinical Lymphoma & Myeloma|March 27, 2007
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challengesElias Jabbour, Jorge Cortes, Susan O'Brien, et al.
Pageof 18

Showing results (21-30 of 174) with videos related to

Sort By:
Pageof 18
Drug Design, Development and Therapy|November 19, 2009
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinibRonan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, et al.
Cancer|January 28, 2004
Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignanciesApostolia-Maria Tsimberidou, Francis Giles, Jorge Romaguera, et al.
Cancer|January 13, 2004
Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center seriesApostolia-Maria Tsimberidou, Francis Giles, Madeleine Duvic, et al.
Annals of Internal Medicine|December 21, 2006
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistanceHagop M Kantarjian, Moshe Talpaz, Francis Giles, et al.
Expert Opinion on Investigational Drugs|November 18, 2008
Deforolimus (AP23573) a novel mTOR inhibitor in clinical developmentMonica Mita, Kamalesh Sankhala, Issam Abdel-Karim, et al.
Leukemia & Lymphoma|April 11, 2015
Novel therapies for myelofibrosisBrady L Stein, Francisco Cervantes, Francis Giles, et al.
Targeted Oncology|April 22, 2009
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agentsKamalesh Sankhala, Alain Mita, Kevin Kelly, et al.
Pediatric Physical Therapy : the Official Publication of the Section on Pediatrics of the American Physical Therapy Association|November 18, 2011
Predictors of Standardized Walking Obstacle Course outcome measures in children with and without developmental disabilitiesKaren M Kott, Sharon L Held, Elizabeth Francis Giles, et al.
Cancer|February 6, 2009
Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulationsTai-Sung Lee, Wanlong Ma, Xi Zhang, et al.
Clinical Lymphoma & Myeloma|March 27, 2007
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challengesElias Jabbour, Jorge Cortes, Susan O'Brien, et al.
Pageof 18